Книга О чем молчит печень. Как уловить сигналы самого крупного внутреннего органа, который предпочитает оставаться в тени, страница 60. Автор книги Сергей Вялов

Разделитель для чтения книг в онлайн библиотеке

Онлайн книга «О чем молчит печень. Как уловить сигналы самого крупного внутреннего органа, который предпочитает оставаться в тени»

Cтраница 60

8. [Guideline] Manns M.P., Czaja A.J., Gorham J.D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun. 51 (6): 2193–2213.

Часть 2. Глава 7

1. Gottesman L.E., Del Vecchio M.T., Aronoff S.C. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr. 2015 Nov 20. 15: 192.

2. Gotze T., Blessing H., Grillhosl C., Gerner P., Hoerning A. Neonatal cholestasis – differential diagnoses, current diagnostic procedures, and treatment. Front Pediatr. 2015. 3: 43.

3. Davis A.R., Rosenthal P., Escobar G.J., Newman T.B. Interpreting conjugated bilirubin levels in newborns. J Pediatr. 2011 Apr. 158 (4): 562–565.e1.

4. Memon N., Weinberger B.I., Hegyi T., Aleksunes L.M. Inherited disorders of bilirubin clearance. Pediatr Res. 2016 Mar. 79 (3): 378–386.

5. van Dijk R., Beuers U., Bosma P.J. Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol. 2015 Jun. 48 (2–3): 243–253.

6. Sticova E., Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013 Oct 14. 19 (38): 6398–6407.

Часть 2. Глава 8

1. Stanley S.L. Jr. Amoebiasis. Lancet. 2003 Mar 22. 361 (9362): 1025–1034.

2. Acuna-Soto R., Maguire J.H., Wirth D.F. Gender distribution in asymptomatic and invasive amebiasis. Am J Gastroenterol. 2000 May. 95 (5): 1277–1283.

3. Ralston K.S., Petri WA Jr. Tissue destruction and invasion by Entamoeba histolytica. Trends Parasitol. 2011 Jun. 27 (6): 254–263.

4. Tanyuksel M., Petri W.A. Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev. 2003 Oct. 16 (4): 713–729.

5. Maltz G., Knauer C.M. Amebic liver abscess: a 15-year experience. Am J Gastroenterol. 1991 Jun. 86 (6): 704–710.

6. [Guideline] World Health Organization. Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups.

7. Dold C., Holland C.V. Ascaris and ascariasis. Microbes Infect. 2011 Jul. 13 (7): 632–637.

8. Gangopadhyay A.N., Upadhyaya V.D., Gupta D.K. et al. Conservative treatment for round worm intestinal obstruction. Indian J Pediatr. 2007 Dec. 74 (12): 1085–1087.

9. Das A.K. Hepatic and biliary ascariasis. J Glob Infect Dis. 2014 Apr. 6 (2): 65–72.

10. Wani I. Gallbladder ascariasis. Turk J Gastroenterol. 2011. 22 (2): 178–182.

11. [Guideline] Brunetti E., Kern P., Vuitton D.A, Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010 Apr. 114 (1): 1–16.

12. Macpherson C.N., Bartholomot B., Frider B. Application of ultrasound in diagnosis, treatment, epidemiology, public health and control of Echinococcus granulosus and E. multilocularis. Parasitology. 2003. 127 Suppl: S21–35.

13. Junghanss T., da Silva A.M., Horton J., Chiodini P.L., Brunetti E. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg. 2008 Sep. 79 (3): 301–311.

14. McManus D.P., Zhang W., Li J., Bartley P.B. Echinococcosis. Lancet. 2003 Oct 18. 362 (9392): 1295–1304.

15. Filippou D, Tselepis D, Filippou G, Papadopoulos V. Advances in liver echinococcosis: diagnosis and treatment. Clin Gastroenterol Hepatol. 2007 Feb. 5 (2): 152–159.

16. Parija S.C. Textbook of Medical Parasitology. Protozoology and Helminthology. 4 ed. New Delhi: All India: Publishers and Distributers; 2013.

17. Sakru N., Korkmaz M., Demirci M., Kuman A. Ok U.Z. Fasciola hepatica infection in echinococcosis suspected cases. Turkiye Parazitol Derg. 2011. 35 (2): 77–80.

18. Garcia L.S. Diagnostic Medical Parasitology. 5th ed. Washington, D.C: ASM Press; 2007.

19. Ubeira F.M., Muino L., Valero M.A., Periago M.V., Perez-Crespo I., Mezo M. MM3-ELISA detection of Fasciola hepatica coproantigens in preserved human stool samples. Am J Trop Med Hyg. 2009 Jul. 81 (1): 156–162.

20. Ezzat R.F., Karboli T.A., Kasnazani K.A., Hamawandi A.M.. Endoscopic management of biliary fascioliasis: a case report. J Med Case Rep. 2010 Mar 6. 4: 83.

Часть 2. Глава 9

1. Fleming R.E., Britton R.S., Waheed A. et al. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis. 2004 Nov. 8 (4): 755–773, vii.

2. Adams P.C., Barton J.C. Haemochromatosis. Lancet. 2007 Dec 1. 370 (9602): 1855–1860.

3. Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int. 2009 Jul. 106 (30): 499–504, I.

4. Parkkila S., Niemela O., Britton R.S. et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology. 2001 Dec. 121 (6): 1489–1496.

5. Allen K.J., Gurrin L.C., Constantine C.C. et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 Jan 17. 358 (3): 221–230.

6. Janssen M.C., Swinkels D.W. Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol. 2009. 23 (2): 171–183.

7. Gurrin L.C., Bertalli N.A., Dalton G.W. et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009 Jul. 50 (1): 94–101.

8. Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol. 2016. 10 (3): 359–370.

9. Dusek P., Roos P.M., Litwin T., Schneider S.A., Flaten T.P., Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol. 2015 Jul. 31: 193–203.

10. Rodriguez-Castro K.I., Hevia-Urrutia F.J., Sturniolo G.C. Wilson’s disease: A review of what we have learned. World J Hepatol. 2015 Dec 18. 7 (29): 2859–2870.

11. Schilsky M.L. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017 Nov. 21 (4): 755–767.

12. Roberts E.A., Schilsky M.L. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008 Jun. 47 (6): 2089–2111.

13. Weiss K.H., Thurik F., Gotthardt D.N. et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013 Aug. 11 (8): 1028–1035.e2.

14. Gerosa C., Fanni D., Congiu T. et al. Liver pathology in Wilson’s disease: from copper overload to cirrhosis. J Inorg Biochem. 2019 Jan 15. 193: 106–111.

Часть 2. Глава 10

1. Solis Herruzo J.A., Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Rev Esp Enferm Dig. 2009 Jun. 101 (6): 413–423.

Вход
Поиск по сайту
Ищем:
Календарь
Навигация